Fresenius Medical (FMS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.65
- EPS estimate
- $0.63
- EPS surprise
- +2.62%
- Revenue surprise
- +2.02%
- Revenue
- $5.6B
- Revenue estimate
- $5.5B
- Reported
- Aug 3, 2026
Fresenius Medical Care reported Q2 2026 results on August 3, 2026. Earnings per share were $0.65, ahead of the $0.63 estimate by 2.62%. Revenue was $5.6 billion, 2.02% above the $5.5 billion estimate. Compared with Q2 2025, EPS rose about 23% from $0.53, and revenue edged up from $5.5 billion.
Revenue has been broadly stable, between $4.8 billion and $6.0 billion a quarter across the table, while earnings have grown. Annual EPS was $1.61 in 2022 and dipped to $1.39 in 2023, then rose to $1.67 in 2024 and $2.49 in 2025, up about 49%. The first half of 2026 totals $1.18, about 17% above the first half of 2025. Q4 2025 set the highs in the table at $0.85 per share and $6.0 billion in revenue. The EPS low is $0.29, from Q1 2023. Over the last 20 quarters, the company beat the EPS estimate 17 times. The most recent miss was Q1 2026, at 3.15% below.
Fresenius Medical Care reported Q3 results between October 31 and November 5 in each of the past five years. That points to early November 2026 for the next report. It will show whether EPS keeps running above year-earlier levels.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | $0.63 | $0.65 | +2.62% | $5.6B | SEC |
| Q1 2026 | May 5, 2026 | $0.55 | $0.53 | −3.15% | $5.4B | SEC |
| Q4 2025 | Feb 24, 2026 | $0.67 | $0.85 | +26.81% | $6.0B | SEC |
| Q3 2025 | Nov 4, 2025 | $0.59 | $0.63 | +6.34% | $5.6B | SEC |
| Q2 2025 | Aug 5, 2025 | $0.51 | $0.53 | +4.05% | $5.5B | SEC |
| Q1 2025 | May 6, 2025 | $0.43 | $0.48 | +11.88% | $5.5B | SEC |
| Q4 2024 | Feb 25, 2025 | $0.42 | $0.48 | +12.90% | $5.3B | SEC |
| Q3 2024 | Nov 5, 2024 | $0.38 | $0.45 | +18.29% | $5.3B | SEC |
| Q2 2024 | Jul 30, 2024 | $0.37 | $0.38 | +2.00% | $5.1B | SEC |
| Q1 2024 | May 7, 2024 | $0.28 | $0.36 | +27.06% | $5.1B | SEC |
| Q4 2023 | Feb 20, 2024 | $0.44 | $0.48 | +8.92% | $5.4B | SEC |
| Q3 2023 | Nov 2, 2023 | $0.29 | $0.30 | +5.22% | $5.2B | SEC |
| Q2 2023 | Aug 2, 2023 | $0.29 | $0.32 | +11.72% | $5.3B | SEC |
| Q1 2023 | May 9, 2023 | $0.24 | $0.29 | +19.92% | $5.2B | SEC |
| Q4 2022 | Feb 21, 2023 | $0.31 | $0.46 | +49.04% | $5.3B | SEC |
| Q3 2022 | Oct 31, 2022 | $0.35 | $0.40 | +15.41% | $5.3B | — |
| Q2 2022 | Aug 2, 2022 | $0.40 | $0.39 | −2.29% | $4.9B | — |
| Q1 2022 | May 4, 2022 | $0.36 | $0.36 | +0.56% | $4.8B | — |
| Q4 2021 | Feb 22, 2022 | $0.50 | $0.51 | +2.06% | $5.3B | — |
| Q3 2021 | Nov 2, 2021 | $0.55 | $0.54 | −1.45% | $5.1B | — |
Quarterly revenue
Frequently asked questions
When did Fresenius Medical (FMS) last report earnings?
Fresenius Medical last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did FMS beat earnings estimates?
Yes. Fresenius Medical reported EPS of $0.65 for Q2 2026 against a $0.63 estimate — a 2.62% beat.
How much revenue did FMS report last quarter?
Fresenius Medical reported $5.6B in revenue for Q2 2026, against a consensus estimate of $5.5B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.